The SCLC-A-CRIP2 cluster accounted for 69.08% (range, 0–96.82%) of the pretreatment samples, and 33.33% (0–100%) of all cancer cells in the posttreatment samples (Fig. 3i), suggesting its potential role in drug resistance and relapse. This evidence concerns the gene CRIP2 and small cell lung carcinoma.